Literature DB >> 25932219

Efficiencies of intracoronary sodium nitroprusside on fractional flow reserve measurement.

Shaosheng Li1, Jie Deng2, Xiaozeng Wang2, Xin Zhao2, Yaling Han2.   

Abstract

BACKGROUND: Fractional flow reserve (FFR) has certain advantages of assessing functional severity of coronary stenosis. Adenosine(AD) is the most widely used agents in FFR measurement but has the disadvantages of higher rate of complications. Sodium Nitroprusside (SNP) represents a valuable alternative. METHODS AND
RESULTS: In 75 patients with 86 moderate coronary stenosis, FFR values, heart rate and blood pressure were measured at baseline, after 0.6 μg boluses of intracoronary (IC) SNP, and after 140 μg/kg /min of continuous intravenous (IV) AD. FFR values decreased significantly after administering IV AD and IC SNP compared with the baseline Pd/Pa values (P < 0.001). Mean FFR induced by IV AD was not significantly different from that by IC SNP (t = 0.577, P = 0.566). The mean kappa value in the evaluation of two methods was 0.973 for FFR. There was a significant correlation between the FFR values of IV AD and IC SNP (R = 0.911, P < 0.001). Significant decreases in the blood pressures were found after agents were given compared to the baseline. No significant difference was found between AD and SNP. In addition, immediate complications occurred in 60.5% patients of IV AD in contrast to no adverse events after IC SNP.
CONCLUSION: SNP is a safe and effective agent and easy to use for the FFR measurement. Maximal hyperemia by IC SNP is equivalent to that by IV AD. IC SNP could be considered a potential alternative in patients with contraindications to AD administration.

Entities:  

Keywords:  Fractional flow reserve; coronary angiography; coronary artery disease

Year:  2015        PMID: 25932219      PMCID: PMC4402866     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  12 in total

1.  Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease.

Authors:  William F Fearon; Bernhard Bornschein; Pim A L Tonino; Raffaella M Gothe; Bernard De Bruyne; Nico H J Pijls; Uwe Siebert
Journal:  Circulation       Date:  2010-11-29       Impact factor: 29.690

2.  Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study.

Authors:  Nico H J Pijls; Pepijn van Schaardenburgh; Ganesh Manoharan; Eric Boersma; Jan-Willem Bech; Marcel van't Veer; Frits Bär; Jan Hoorntje; Jacques Koolen; William Wijns; Bernard de Bruyne
Journal:  J Am Coll Cardiol       Date:  2007-05-17       Impact factor: 24.094

3.  Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve.

Authors:  B de Bruyne; J Bartunek; S U Sys; N H Pijls; G R Heyndrickx; W Wijns
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

4.  Effects of intracoronary sodium nitroprusside compared with adenosine on fractional flow reserve measurement.

Authors:  Xiaozeng Wang; Shaosheng Li; Xin Zhao; Jie Deng; Yaling Han
Journal:  J Invasive Cardiol       Date:  2014-03       Impact factor: 2.022

5.  Patients with coronary stenosis and a fractional flow reserve of ≥0.75 measured in daily practice at the VU University Medical Center.

Authors:  N Oud; K M Marques; J G F Bronzwaer; S Brinckman; C P Allaart; C C de Cock; Y Appelman
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

6.  Meta-analysis of fractional flow reserve versus quantitative coronary angiography and noninvasive imaging for evaluation of myocardial ischemia.

Authors:  Maria A C Christou; George C M Siontis; Demosthenes G Katritsis; John P A Ioannidis
Journal:  Am J Cardiol       Date:  2006-12-20       Impact factor: 2.778

7.  Usefulness of the fractional flow reserve derived by intracoronary pressure wire for evaluating angiographically intermediate lesions in acute coronary syndrome.

Authors:  Ramón López-Palop; Pilar Carrillo; Araceli Frutos; Jesús Castillo; Alberto Cordero; Marlon Toro; Vicente Bertomeu-Martínez
Journal:  Rev Esp Cardiol       Date:  2010-06       Impact factor: 4.753

8.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors:  M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

9.  Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve.

Authors:  Wojciech Rudzinski; Alfonso H Waller; Arthur Rusovici; Abed Dehnee; Ali Nasur; Michael Benz; Salvador Sanchez; Marc Klapholz; Edo Kaluski
Journal:  Catheter Cardiovasc Interv       Date:  2012-10-15       Impact factor: 2.692

10.  Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire.

Authors:  B De Bruyne; N H Pijls; W J Paulus; P J Vantrimpont; S U Sys; G R Heyndrickx
Journal:  J Am Coll Cardiol       Date:  1993-07       Impact factor: 24.094

View more
  3 in total

Review 1.  Coronary physiology assessment in the catheterization laboratory.

Authors:  Felipe Díez-Delhoyo; Enrique Gutiérrez-Ibañes; Gerard Loughlin; Ricardo Sanz-Ruiz; María Eugenia Vázquez-Álvarez; Fernando Sarnago-Cebada; Rocío Angulo-Llanos; Ana Casado-Plasencia; Jaime Elízaga; Francisco Fernández Avilés Diáz
Journal:  World J Cardiol       Date:  2015-09-26

2.  Comparative efficacy and safety of adenosine and regadenoson for assessment of fractional flow reserve: A systematic review and meta-analysis.

Authors:  Gauravpal Singh Gill; Akshaya Gadre; Arun Kanmanthareddy
Journal:  World J Cardiol       Date:  2022-05-26

3.  Utility of Saline-Induced Resting Full-Cycle Ratio Compared with Resting Full-Cycle Ratio and Fractional Flow Reserve.

Authors:  Takao Sato; Sonoka Goto; Yusuke Ohta; Yuji Taya; Sho Yuasa; Minoru Takahashi; Masaaki Okabe; Yoshifusa Aizawa
Journal:  J Interv Cardiol       Date:  2020-04-06       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.